flora peyvandi/X
Dec 8, 2025, 07:42
Flora Peyvandi: Anti-emicizumab Antibodies and Their Relevance in Clinical Practice
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
“The development of anti-emicizumab antibodies is a rare event, particularly those with neutralizing activity. Routine monitoring should be reserved only for patients with clinical manifestations of bleeding when therapy failure is suspected.”
Title: Anti-emicizumab antibodies and their relevance in clinical practice
Authors: Carla Valsecchi, Lucia Schiavone, Sara Arcudi, Adriana Torri, Cristina Novembrino, Flora Peyvandi
Read the full article.
More posts featuring Flora Peyvandi on Hemostasis Today.
-
Mar 12, 2026, 12:05Kent H: The Lymphatic System – The Unsung Hero of Detox
-
Mar 12, 2026, 11:55Akinchan Bhardwaj: Exercise Biological Modifier of Vascular Trajectory
-
Mar 12, 2026, 11:50Guy Young: Clinical Conversations on Gene Therapy Progress in Hemophilia B at THSNA 2026
-
Mar 12, 2026, 11:44Yves Bikorimana: Causes, Diagnosis, and Management of Neonatal Alloimmune Thrombocytopenia
-
Mar 12, 2026, 11:33Kymentie Ferdinande: New Insights Into Platelet Function and Thrombus Formation in Cirrhosis
-
Mar 12, 2026, 11:17Tareq Abadl: Why Do Some People Bruise And Bleed So Easily?
-
Mar 12, 2026, 11:15Matthew Flick: The Interplay of the Fibrinogen αC-Region, Hypofibrinogenemia, and GPVI in Arterial Thrombosis
-
Mar 12, 2026, 11:08Stephen Twumasi: The Impact of Hepatitis B Infection on the Coagulation System During Pregnancy
-
Mar 12, 2026, 11:05Robert Lufkin: One Minute of Wisdom from Robert Lustig on Cholesterol, Sugar, and Heart Disease